Valuation: Immunome, Inc.

Market Cap 2.04B 1.81B 1.68B 1.52B 2.86B 193B 2.91B 20.15B 7.91B 101B 7.63B 7.48B 322B P/E 2026 *
-7.61x
P/E 2027 * -6.93x
Enterprise Value 1.79B 1.59B 1.48B 1.34B 2.52B 170B 2.56B 17.74B 6.97B 88.82B 6.72B 6.58B 283B EV / Sales 2026 *
6,719x
EV / Sales 2027 * 37.8x
Free-Float
93.68%
Yield 2026 *
-
Yield 2027 * -
1 day+6.86%
1 week+1.93%
Current month-16.69%
1 month-25.24%
3 months-19.13%
6 months-26.10%
Current year-16.57%
1 week 16.41
Extreme 16.41
18.27
1 month 16.41
Extreme 16.41
25.94
Current year 16.41
Extreme 16.41
30.06
1 year 14.64
Extreme 14.64
30.06
3 years 5.15
Extreme 5.1501
30.96
5 years 2.09
Extreme 2.09
30.96
10 years 2.09
Extreme 2.09
63.78
Manager TitleAgeSince
Chief Executive Officer 65 2023-10-01
Director of Finance/CFO 36 2024-01-01
Chief Tech/Sci/R&D Officer 58 2024-06-26
Director TitleAgeSince
Director/Board Member 55 2016-12-31
Chairman 65 2023-10-01
Director/Board Member 58 2023-10-01
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Exercice

Chief Technology Officer

58,000 0.0511%
8/12/26 Sell

Director

-11,048 0.0098%
8/6/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+6.86%+1.93%+10.28%+105.27% 2.04B
+0.79%-6.16%+49.32%+74.50% 66.34B
-0.26%+10.35%+13.02%+87.74% 52.92B
-0.44%+3.56%+6.15%+71.39% 54.82B
+0.74%+2.75%+26.31%+45.29% 44.09B
+3.87%+10.15%+20.69%+132.73% 43.72B
+7.91%+4.30%+263.91%+602.72% 42.13B
-0.40%+9.85%+17.04%+59.17% 33.96B
-1.98%-1.33%+36.26%+6.35% 26.17B
-0.31%+5.34%+30.98%+26.07% 23.37B
Average +1.65%+1.69%+47.40%+121.12% 38.95B
Weighted average by Cap. +1.21%+1.99%+50.71%+127.56%

Financials

2026 *2027 *
Net sales 267K 237K 220K 199K 375K 25.26M 381K 2.64M 1.04M 13.22M 1M 980K 42.17M 50.41M 44.87M 41.59M 37.68M 70.82M 4.78B 72.01M 499M 196M 2.5B 189M 185M 7.97B
Net income -273M -243M -225M -204M -383M -25.85B -390M -2.7B -1.06B -13.53B -1.02B -1B -43.15B -315M -280M -260M -235M -442M -29.8B -449M -3.11B -1.22B -15.6B -1.18B -1.16B -49.76B
Net Debt -244M -217M -201M -182M -342M -23.08B -348M -2.41B -947M -12.08B -914M -895M -38.53B -132M -117M -109M -98.35M -185M -12.46B -188M -1.3B -512M -6.52B -494M -483M -20.81B
Projected Income Statement - Annual - Immunome, Inc.
Logo Immunome, Inc.
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Employees
247
Date Price Change Volume
26-10-20 US$17.92 +6.86% 2,029,591
26-10-19 US$16.77 +1.82% 1,139,956
26-10-16 US$16.47 -5.34% 1,299,733
26-10-15 US$17.40 +1.16% 1,621,275
26-10-14 US$17.20 -2.16% 1,155,226
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Immunome, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
17.92USD
Average target price
35.19USD
Spread / Average Target
+96.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immunome, Inc.
  1. Stock Market
  2. Stocks
  3. IMNM Stock